Back of the Eye Disorders Market By Product Type (Pharmaceutical Therapies, Vitreoretinal Surgical Systems and Consumables, Retinal Diagnostic and Monitoring Systems); By Application (Age-Related Macular Degeneration, Diabetic Retinopathy and Diabetic Macular Oedema, Retinal Vein Occlusion, Geographic Atrophy, Retinal Detachment and Retinal Tears, Macular Hole and Epiretinal Membrane, Inherited Retinal Diseases); By End User (Hospitals, Ophthalmology and Retina Clinics, Ambulatory Surgical Centres, Research and Academic Institutions, Specialty Eye Care Centers); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Back of the Eye Disorders Market: Recurring Retinal Therapies, Surgical Demand, and the Shift Toward Longer-Acting Treatment

The Global Back of the Eye Disorders Market was valued at USD 23.25 billion in 2025 and is projected to reach USD 35.90 billion by 2032, expanding at a CAGR of 6.4% during 2026–2032, according to Strategic Market Research.

 

Back-of-the-eye disorders such as AMD, Diabetic Retinopathy, and Geographic Atrophy are increasingly managed through mechanism-driven therapeutic approaches. Current approved treatments mainly focus on inhibiting abnormal blood vessel growth through anti-VEGF therapies and controlling inflammation. The evolving pipeline is exploring advanced solutions, including gene therapies, cell replacement strategies, tyrosine kinase inhibitors (TKIs), and sustained drug delivery platforms. These innovations aim to improve treatment outcomes, slow disease progression, and reduce the frequency of repeated eye injections, enhancing patient convenience and long-term care.

 

A Large Disease Base Narrows Substantially Before Treatment Begins

The US provides one of the clearest publicly documented patient bases. Approximately 19.8 million Americans aged 40 years or older were living with age-related macular degeneration in 2019, including around 1.49 million with vision-threatening disease. The vision-threatening group represented approximately 7.5% of the wider AMD population and is commercially more relevant to active treatment demand.

An estimated 9.6 million people in the US had diabetic retinopathy in 2021, including approximately 1.84 million with vision-threatening diabetic retinopathy. This higher-intensity group accounted for about 19.2% of the total diabetic retinopathy population and provides a closer indication of the potential pool for injections, laser treatment, and vitreoretinal surgery.

Commercial demand is concentrated among patients who develop active neovascularisation, diabetic macular oedema, geographic atrophy eligible for treatment, retinal vein occlusion with macular oedema, vitreous haemorrhage, traction, or retinal detachment. Early AMD and mild diabetic retinopathy generally contribute more to monitoring and imaging activity than to direct pharmaceutical revenue.

The patient pathway moves from diagnosis and specialist referral to treatment eligibility, payer approval, initiation, and continued attendance. Revenue can be lost through delayed diagnosis, poor access to retina specialists, affordability pressure, injection fatigue, clinic congestion, treatment discontinuation, and loss to follow-up. Providers and suppliers that reduce these gaps can improve persistence and increase the proportion of eligible patients who reach active care.

 

Recurring Injections Create the Strongest Verified Revenue Stream

Anti-VEGF treatment remains the most established recurring commercial pathway within the market. These medicines are administered for neovascular AMD, diabetic macular oedema, diabetic retinopathy, and macular oedema associated with retinal vein occlusion. Each treated eye can generate medicine revenue, an injection-administration event, retinal imaging, clinical review, and follow-up appointments.

The UK National Ophthalmology Database recorded 26,847 eyes starting neovascular AMD treatment during the 2021 NHS year. These eyes received 162,139 injections during the first treatment year, equivalent to just over six treatment events for every eye entering the pathway.

A separate two-year cohort included 12,171 eyes that received 139,205 injections, with a median of 12 injections over 24 months. The figures demonstrate that commercial value continues well beyond the initial treatment cycle. However, 38.9% of otherwise eligible eyes had no recorded follow-up within the month-24 assessment window, showing how loss to follow-up can reduce lifetime treatment revenue.

Australia provides another strong utilisation trend. Reimbursed intravitreal-injection claims increased from 181,140 in 2012 to 621,001 in 2022. This represents growth of approximately 243% over ten years and an implied service-volume CAGR of about 13.1%.

Treatment burden is therefore a commercial issue rather than only a clinical inconvenience. Frequent appointments consume specialist capacity, imaging resources, pharmacy handling, and injection-chair time. Medicines that maintain disease control with fewer annual injections can compete through reduced service pressure, stronger patient retention, and additional capacity for new treatment starts.

 

Competitive Value Is Shifting Within the Anti-VEGF Segment

The current anti-VEGF market contains three competing value models: lower-cost established treatment, differentiated branded medicines offering longer intervals or additional biological targets, and higher-dose formulations intended to extend disease control.

Roche reported Vabysmo sales of CHF 2.059 billion during the first half of 2026, representing growth of 8% at constant exchange rates. The US generated CHF 1.333 billion, accounting for approximately 64.7% of global Vabysmo sales during the period. Europe contributed CHF 386 million, or about 18.7%, while Japan represented 3.6% with CHF 75 million. Other international markets contributed CHF 265 million, equivalent to approximately 12.9% of the product’s global revenue.

Regeneron reported US net sales of USD 468 million for EYLEA HD in the first quarter of 2026, an increase of 52% from the corresponding period. Combined US sales of EYLEA HD and the original EYLEA product were USD 941 million, down 10%.

EYLEA HD therefore accounted for approximately 49.7% of the combined US EYLEA franchise during the quarter, compared with about 50.3% for the original formulation. The near-even revenue mix shows how quickly value is shifting toward higher-dose treatment, even as the overall franchise faces pricing, contracting, and switching pressure.

Competitive concentration is also visible in publicly reimbursed diabetic macular oedema treatment in Australia. During 2022–2023, aflibercept represented 81% of Pharmaceutical Benefits Scheme items in this subsegment, compared with 14% for ranibizumab and 5% for faricimab. These shares demonstrate the strength of the incumbent product while also showing an emerging reimbursed pathway for newer competitors.

The US Food and Drug Administration’s approval of Yesafili and Opuviz in May 2024 as the first interchangeable biosimilars to Eylea gives payers and purchasing organisations additional leverage. Updated NHS commissioning recommendations similarly favour biosimilar aflibercept or ranibizumab as best-value first-line options in relevant retinal vascular pathways.

 

Geographic Atrophy Has Become a Recurring Treatment Category

Advanced dry AMD previously generated extensive monitoring and imaging activity but limited pharmaceutical revenue. FDA approvals for Syfovre in February 2023 and Izervay in August 2023 created a recurring injection segment for geographic atrophy secondary to AMD.

Syfovre generated approximately USD 587 million in full-year 2025 net product revenue. Apellis’ two commercial products, Syfovre and Empaveli, generated combined 2025 net product revenue of approximately USD 689 million, meaning Syfovre contributed about 85.2% of the company’s disclosed commercial product revenue.

Syfovre also generated USD 150.7 million in US net product revenue during the first quarter of 2026, compared with USD 130.2 million in the first quarter of 2025. This represented year-on-year growth of approximately 15.7%, confirming continued revenue expansion within the geographic atrophy treatment subsegment.

In May 2026, Biogen completed its acquisition of Apellis Pharmaceuticals in a transaction valued at approximately USD 5.6 billion. The transaction value was more than eight times Apellis’ combined 2025 commercial product revenue, reflecting the strategic value placed on Syfovre, Empaveli, and the wider complement-focused development portfolio.

Geographic atrophy remains commercially different from conventional anti-VEGF treatment. These therapies slow lesion progression rather than restore lost vision. Revenue growth therefore depends on patient selection, treatment persistence, safety confidence, payer coverage, and whether providers can communicate the long-term value of delaying irreversible vision loss.

 

Vitreoretinal Surgery Operates Through a Separate Demand Model

Retinal detachment, macular hole, epiretinal membrane, tractional diabetic retinal disease, and non-clearing vitreous haemorrhage create procedure-based rather than prescription-based demand. Commercial value is tied to annual case incidence, urgency, surgeon availability, operating capacity, reimbursement, and procedure-specific supplies.

A CMS analysis found that retinal-detachment repair code 67108 was billed 16,523 times to Medicare Part B in 2019 and 14,871 times in 2020. The 10% reduction during 2020 largely reflects pandemic-related disruption rather than a structural fall in underlying disease incidence.

UK hospital episodes for retinal detachment with breaks increased from 3,447 in 2000 to 10,971 in 2022. This represented cumulative growth of approximately 218% and an implied annual growth rate of about 6.6% over the 18-year period, indicating a sustained increase in hospital vitreoretinal workload.

Most surgical revenue is concentrated around one treatment episode. That episode may include vitrectomy systems, viewing equipment, laser use, probes, instruments, gases, silicone oils, fluids, disposable packs, and post-operative care. Revision surgery, recurrent detachment, silicone-oil removal, or disease in the other eye can create additional demand, but repeat revenue remains less predictable than pharmaceutical maintenance.

ZEISS completed its acquisition of Dutch Ophthalmic Research Center in April 2024. DORC supplies vitreoretinal surgical systems and consumables, while ZEISS reported a final accounting purchase price of approximately EUR 1.024 billion. DORC contributed EUR 99.9 million following its initial consolidation in fiscal 2023–2024, providing a direct commercial signal for the value of retinal surgical equipment and recurring procedure supplies.

 

Pipeline Investment Is Concentrated on Treatment Durability

The most commercially significant retinal pipeline programmes are designed to reduce repeated injections, provide continuous local drug exposure, or reach diseases with limited treatment options. Reducing visits can improve treatment persistence and allow retina services to manage more patients without a proportional increase in staffing.

ABBV-RGX-314, also known as surabgene lomparvovec, is being developed by AbbVie and REGENXBIO as an AAV-based gene therapy intended to produce an anti-VEGF protein within the eye. Both subretinal and suprachoroidal delivery routes are under investigation. A successful infrequently administered treatment could shift revenue from recurring injections toward a higher-value upfront therapy.

4D Molecular Therapeutics is developing 4D-150 as an intravitreal gene therapy expressing aflibercept alongside an anti-VEGF-C component. The company completed enrolment in the 4FRONT-2 Phase 3 study in June 2026, while results from 4FRONT-1 are expected during the first half of 2027. Its intravitreal route may support broader adoption than programmes requiring surgical subretinal administration.

Ocular Therapeutix is evaluating AXPAXLI, an axitinib-containing intravitreal hydrogel implant, in Phase 3 wet AMD trials. Its commercial proposition is sustained local treatment without permanent hardware or frequent injections.

Merck’s MK-3000, acquired through EyeBio and previously known as Restoret or EYE103, targets the Wnt-signalling pathway involved in vascular stability. Two registrational diabetic macular oedema studies were fully enrolled by April 2026, positioning the programme as a potential competitor outside conventional VEGF-only treatment.

Ray Therapeutics is developing optogenetic programmes for advanced retinal degeneration. RTx-015 received US RMAT and European PRIME designations in April 2026, while RTx-021 is being developed for conditions including Stargardt disease and geographic atrophy. These earlier-stage programmes could create treatment demand among patients who currently have few commercial options.

 

Provider Capacity Determines How Much Eligible Demand Becomes Revenue

Retina services require appointment availability, imaging, medicine handling, trained injectors, authorisation support, and reliable follow-up systems. Capacity pressure is especially important in publicly funded systems where treatment volume can rise faster than specialist staffing.

In the UK AMD audit, nurses administered 62.5% of recorded first-year injections, compared with 23.6% administered by doctors. Nurses therefore delivered approximately 2.6 times as many injections as doctors within the reported cohort. The remaining activity was delivered by other trained staff or recorded under different provider categories.

Task sharing allows retina specialists to supervise larger treatment populations without personally delivering every injection. It also increases the commercial importance of trained non-medical staff, standardised protocols, and efficient clinic workflow.

Longer-acting products compete partly by releasing capacity. Fewer annual visits can reduce congestion and allow providers to initiate treatment for additional patients. Surgery has a different capacity constraint because vitreoretinal procedures depend on trained surgeons, operating-theatre access, emergency scheduling, and specialised equipment.

 

Regional Commercial Conditions Differ More Than Disease Biology

The US combines a large documented disease base, physician-administered drug reimbursement, specialist retina practices, and strong branded medicine sales. It accounted for approximately 64.7% of Vabysmo’s global sales during the first half of 2026 and generated the full USD 941 million combined EYLEA franchise revenue reported by Regeneron for the first quarter.

The UK represents a high-volume publicly funded market shaped by national procurement and capacity constraints. Its 162,139 first-year injections across 26,847 treated eyes show substantial recurring demand, while biosimilar-first recommendations restrict originator pricing power.

Australia recorded 621,001 reimbursed intravitreal-injection claims in 2022, following an implied 13.1% CAGR in service volume from 2012. Within reimbursed diabetic macular oedema medicines, aflibercept held an 81% share of PBS items during 2022–2023.

Europe generated CHF 386 million, or approximately 18.7%, of Vabysmo’s first-half 2026 revenue. Japan contributed CHF 75 million and recorded 26% growth at constant exchange rates. Other international markets generated CHF 265 million and expanded by 65%, making them the fastest-growing geographic component of the product’s reported sales mix.

 

Market Constraints and Revenue Risks

Treatment persistence remains a major revenue uncertainty. Missed appointments, limited perceived improvement, travel requirements, injection anxiety, co-payments, and declining general health can reduce the number of completed treatments per eligible eye.

Biosimilars and off-label bevacizumab create sustained pricing pressure in mature anti-VEGF indications. Treatment volumes may increase while branded revenue per injection declines. Originator companies must defend value through longer dosing intervals, additional indications, contracting, patient support, or stronger outcomes.

Geographic atrophy therapies face a different adoption challenge because their value lies in slowing progression rather than restoring vision. Gene therapies and sustained-delivery products could reduce conventional injection volumes if they achieve durable control, but they may also expand the treated population by improving persistence and releasing clinic capacity.

Surgical demand is less exposed to pharmaceutical pricing but remains constrained by capital budgets, surgeon availability, operating capacity, and uneven access to specialist centres.

 

Strategic Market Assessment

The Back of the Eye Disorders Market is projected to expand at a CAGR of 6.4%, increasing from USD 23.25 billion in 2025 to USD 35.90 billion by 2032. Recurring pharmaceutical treatment currently provides the strongest utilisation and company-revenue base, while vitreoretinal surgery supports a separate market for capital systems, consumables, and services.

Commercial value is shifting from undifferentiated anti-VEGF dosing toward several competing positions. Lower-cost biosimilars are gaining payer support, EYLEA HD represented 49.7% of the combined US EYLEA franchise in the first quarter of 2026, and Vabysmo generated CHF 2.059 billion in first-half revenue with an 8% growth rate. Geographic atrophy has also become a material subsegment, with Syfovre generating USD 587 million in 2025 and representing 85.2% of Apellis’ combined commercial product revenue.

 

Back of the Eye Disorders Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 23.25 Billion
Revenue Forecast in 2032	USD 35.90 Billion
Overall Growth Rate	CAGR of 6.4% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product Type, By Application, By End User, By Region
By Product Type	Pharmaceutical Therapies, Vitreoretinal Surgical Systems and Consumables, Retinal Diagnostic and Monitoring Systems
By Application	Age-Related Macular Degeneration, Diabetic Retinopathy and Diabetic Macular Oedema, Retinal Vein Occlusion, Geographic Atrophy, Retinal Detachment and Retinal Tears, Macular Hole and Epiretinal Membrane, Inherited Retinal Diseases
By End User	Hospitals, Ophthalmology and Retina Clinics, Ambulatory Surgical Centres, Research and Academic Institutions, Specialty Eye Care Centers
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Increasing prevalence of retinal disorders among ageing populations, rising adoption of advanced retinal imaging and monitoring technologies, growing demand for minimally invasive vitreoretinal procedures and targeted ophthalmic therapies
Customization Option	Available upon request